PLAINSBORO, N.J., Oct. 26, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has made Forbes magazine's 2010 list of "America's 100 Best Small Companies." This is the third consecutive year and the sixth time in the last seven years that Integra has been named to Forbes list of "Best Small Companies."
"It's very gratifying to be recognized by such a well respected source as Forbes and we're honored to have been named to Forbes 100 Best Small Companies," said Stuart Essig, Integra's President and CEO. "Integra's success is a testament to our employees, who have helped Integra grow from one product -- an artificial skin used in wound and burn care called INTEGRA® Dermal Regeneration Template -- into a leading medical device company with a wide range of products, dedicated to helping the surgeon limit uncertainty. We look forward to continuing to build upon this success and provide life-saving devices for patients worldwide."
The Forbes 100 Best Small Companies ranking is limited to companies with sales between $5 million and $1 billion and a stock price no lower than $5. A company's ranking is based on return on equity, sales growth, and profit growth over the past 12 months and over five years. Forbes dropped companies that are thinly traded and those with fuzzy accounting or major legal troubles. Forbes also factored in the stock performance of each company compared with that of its peers. Shares of last year's members outpaced the Russell 2000 small-company index by an average of 3 percentage points.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella, Director of Corporate Communications (609) 936-2389 Gianna.sabella@integralife.com
